new info about autifony
The QUIET-1 Study in Tinnitus – A UK study
FAQs
On the assumption that you are reading this as an enquirer to Autifony asking a
question about our tinnitus study, may I first apologise for sending you a
"generic" reply. We are really interested in your issues and how to help people
with tinnitus understand better the details of our study. However, we are now
receiving a large volume of mail and we are unable to spend enough time to
respond individually; instead we are working hard to get the study sites opened
across the UK and get them enrolling people into the study.
Q: There seem to be lots of detailed eligibility criteria to enroll into the study –
why is this and will it mean that I cannot be enrolled?
A:
Our first clinical study last year (2013) was in healthy subjects, young
adult males and a group of older men and women, and was intended to
check the safety of our new drug AUT00063 in people.
The QUIET-1 study is the first study of "063" in people suffering with
tinnitus;
We have to be very careful to test the medication in a uniform group of
subjects whose tinnitus is relatively similar. So we need to have quite
tight eligibility criteria. For example, the tinnitus must not have become
too long-term (6 – 18 months is OK) and must not be too extremely
severe.
We also need to be careful that "063" does not adversely affect other
medicines or other illnesses, so we also need to have restrictions on
certain nervous system illnesses (e.g. Parkinson's disease, MS, myasthenia
gravis etc), as well as some medicines that enter the brain.
If the trial is successful, then we will be able to conduct additional trials
with a broader range of people with tinnitus.
Q: How will I get more details?
A:
We shall constantly update the
www.autifony.com website. Over the
coming weeks we shall list which hospitals will be enrolling patients and
when they will open for the enrollment process. Recruitment will be
open over a period of at least 6 months.
We may even be able to post a telephone number for people to call and
check certain things; we are keen to do this so that people will have a
good idea of whether they might be eligible for the study.
We are likely to inform GPs in the locality of the study sites – but this has
not yet started so please don't contact your practice nurse or your GP yet
– wait until you see the details of your own local area on our website.
Q: how many hospitals will be involved?A:
10 -12 or even more, all in England.
We shall probably be studying up to around 150 study participants so
there will be room for lots, all around the country.
Q: I do not live in the UK. Can I visit the UK and be enrolled in the study? Will
you be opening in other countries such as Ireland, the Netherlands..?
A:
Not this time.
People who enroll in the QUIET-1 study must be resident here in the UK,
have an NHS number, and be registered with a local GP, who will be kept
informed of any patients who enroll.
If this study were to show encouraging effects of AUT00063 [and we are a
very very long way off showing anything at all at the moment, as it is only
just starting] then other studies may follow across a broader range of
people with tinnitus and across different countries.
It is also important to know that the study participants will have to
undertake a number of hospital visits over a period of 8-10 weeks and
this will take considerable time and commitment; around 5 half days out
of your schedule. If you start on the study, we really need you to stick
with it!
Q: I have suffered from tinnitus for well over 18 months. I still don't understand
why can't I be enrolled? Does that mean that this medication will not be able to
help me?
A:
As mentioned above, this is the first trial in subjects with tinnitus, and we
need to take one step at a time as we test the effects of "063". If all goes
well in this study, we will aim in future to broaden out into testing the
drug for people who suffer from different kinds of tinnitus, including
those who have had the condition for longer.